DUBLIN--(BUSINESS WIRE)--
Research and Markets (http://www.researchandmarkets.com/research/gfd7gk/pharmapoint) has announced the addition of the "PharmaPoint: Epilepsy - Italy Drug Forecast and Market Analysis to 2022" report to their offering.
Epilepsy is a brain disorder characterized by spontaneously occurring and recurrent seizures. The market is heavily driven by the sales of antiepileptic drugs (AEDs) targeted at seizure reduction. The AED market is currently dominated by UCB's Keppra and GlaxoSmithKline's Lamictal.
Although both drugs have experienced significant generic erosion, they form the mainstay of epilepsy treatment in the nine markets and will continue to have significant market share during the forecast period.
Other key drugs include older generation AEDs such as Pfizer's Dilantin, Abbott's Depakote, and Novartis' Tegretol and Trileptal which still have significant usage due to their longevity in the market.
However, the AED dominance landscape will continue to shift towards newer generation drugs particularly following the recent market entry of GlaxoSmithKline's Trobalt/Potiga and Eisai's Fycompa which both offer first-in-class mechanisms of action.
The main driver for growth in this market is the launch of new AEDs, the continued uptake of recent AEDs, and the lower-than-average rate of generic substitution in Italy compared with other countries, although this may change during the forecast period due to government cost-cutting strategies.
Key Topics Covered:
1.1 List of Tables
1.2 List of Figures
View post:
Research and Markets: Epilepsy - Italian Drug Forecast and Market Analysis to 2022